Pacira BioSciences, Inc. (PCRX)

Market Cap	1.20B
Revenue (ttm)	702.77M
Net Income (ttm)	-103.73M
Shares Out	46.30M
EPS (ttm)	-2.27
PE Ratio	n/a
Forward PE	9.17
Dividend	n/a
Ex-Dividend Date	n/a

Volume	595,345
Open	25.93
Previous Close	25.93
Day's Range	25.36 - 25.99
52-Week Range	11.16 - 31.64
Beta	0.56
Analysts	Buy
Price Target	29.89 (+15.67%)
Earnings Date	May 8, 2025

About PCRX

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled dos...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2011
• Employees: 790
• Stock Exchange: NASDAQ
• Ticker Symbol: PCRX
• Website: https://www.pacira.com

Analyst Forecast

According to 9 analysts, the average rating for PCRX stock is "Buy." The 12-month stock price forecast is $29.89, which is an increase of 15.67% from the latest price.

Price Target

$29.89

(15.67% upside)

Analyst Consensus: Buy